Publications by authors named "Aziz I Shaibani"
Article Synopsis
- Inclusion body myositis is a common muscle-wasting disease in people over 50, and no effective drug treatment currently exists, prompting research into the oral drug arimoclomol.
- A double-blind, placebo-controlled study was conducted on 152 adults in specialist centers across the USA and the UK, randomly assigning them to receive either arimoclomol or a placebo for 20 months.
- The primary goal was to measure changes in muscle function using the Inclusion Body Myositis Functional Rating Scale, with safety evaluations including all participants who received at least one dose of the medication.
Introduction/aims: It is unknown if patients with neuromuscular diseases prefer in-person or virtual telemedicine visits. We studied patient opinions and preference on virtual versus in-person visits, and the factors influencing such preferences.
Methods: Telephone surveys, consisting of 11 questions, of patients from 10 neuromuscular centers were completed.
Mechanics of dystrophin deficient skeletal muscles in very young mice and effects of age.
Am J Physiol Cell Physiol
August 2021
The MDX mouse is an animal model of Duchenne muscular dystrophy, a human disease marked by an absence of the cytoskeletal protein, dystrophin. We hypothesized that ) dystrophin serves a complex mechanical role in skeletal muscles by contributing to passive compliance, viscoelastic properties, and contractile force production and ) age is a modulator of passive mechanics of skeletal muscles of the MDX mouse. Using an in vitro biaxial mechanical testing apparatus, we measured passive length-tension relationships in the muscle fiber direction as well as transverse to the fibers, viscoelastic stress-relaxation curves, and isometric contractile properties.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to examine the long-term effects of bimagrumab over two years in patients with sporadic inclusion body myositis (sIBM), following an initial core study.
- Participants continued receiving bimagrumab or a placebo every four weeks, with the main outcomes being changes in the 6-minute walk distance and safety.
- Results showed that all treatment groups experienced a decline in mobility over time, with high rates of adverse events; however, bimagrumab did not result in significant clinical benefits, leading to the early termination of the extension study.
Objective: To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG).
Methods: This study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody-positive MG without thymoma.
Background: Inclusion body myositis is an idiopathic inflammatory myopathy and the most common myopathy affecting people older than 50 years. To date, there are no effective drug treatments. We aimed to assess the safety, efficacy, and tolerability of bimagrumab-a fully human monoclonal antibody-in individuals with inclusion body myositis.
View Article and Find Full Text PDFBackground: The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone was superior to prednisone alone in improving clinical status as measured by the Quantitative Myasthenia Gravis (QMG) score in patients with generalised non-thymomatous myasthenia gravis at 3 years. We investigated the long-term effects of thymectomy up to 5 years on clinical status, medication requirements, and adverse events.
Methods: We did a rater-blinded 2-year extension study at 36 centres in 15 countries for all patients who completed the randomised controlled MGTX and were willing to participate.
Background: Thymectomy has been a mainstay in the treatment of myasthenia gravis, but there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial comparing thymectomy plus prednisone with prednisone alone.
Methods: We compared extended transsternal thymectomy plus alternate-day prednisone with alternate-day prednisone alone.
Objective: To evaluate dextromethorphan coadministered with quinidine as treatment of diabetic peripheral neuropathic pain.
Design: In a 13-week, phase 3, randomized controlled trial, 379 adults with daily symmetric diabetic peripheral neuropathy (DPN) leg pain for ≥3 months received double-blind placebo, dextromethorphan/quinidine (DMQ) 45/30 mg, or DMQ 30/30 mg, administered once daily for 7 days and twice daily thereafter. Efficacy measures included four pain rating scales applied daily using patient diaries, and another two applied at five clinic visits.